Supplementary Data 1. Effect of σ1 agonist, compound 1(S), on peripheral inflammatory state [a].

	IFN-γ	TNF-α	IL-17a	IL-4
Sham-vehicle	0.57 (±0.66)	ND	1.05 (±0.20)	0.57 (±0.14)
Sham-1(S) 5 mg kg^{-1}	0.97 (±0.92)	ND	2.90 (±0.92)	0.53 (±0.13)
EAE-vehicle	1.58 (±7.51)	55.56 (±453.60)	6.88 (±33.03)	0.80 (±2.62)
EAE-1(S) 5 mg kg^{-1}	1.31 (±3.55)	117.50 (±134.84)	4.70 (±8.37)	0.44 (±0.75)

[a] Quantification of IFN-γ, TNF-α, IL-17a and IL-4 concentration (pg/ml) in serum was performed by ELISA. Sham-vehicle, sham-1(S) 5 mg kg^{-1}, EAE-vehicle and EAE-1(S) 5 mg kg^{-1} were used with 5–11 animals per treatment group. Mice were immunized to induce EAE and administrated compound 1(S) 5 mg kg^{-1} i.p., as described in Materials and Methods. Sera were collected at the peak of disease (i.e., on day 14±2), when the clinical score for the EAE-vehicle group was 4.0, and for the EAE-1(S) group was 1.5. Data are presented as median±IQR. ND, not detected.

25